Clinical Trial Update: Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a MEK inhibitor to reverse preneoplastic metaplasia in the stomach; the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastric Intestinal Metaplasia

Drugs mentioned

• MEK inhibitor (unspecified) (MEK inhibitor)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Gastric Cancer, Metaplasia | Phase 1 | Status: ACTIVE_NOT_RECRUITING